X4 Pharmaceuticals
x4pharma.com
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026,
Read more
Report
X4 Pharmaceuticals Secures $150M Loan Facility with K2 HealthVentures, Pays Off Hercules Debt
Read more
Report
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
- Repayment of Existing Loan Facility Completed -- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activitie...
Read more
Report
X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures
X4 Pharmaceuticals (NASDAQ:XFOR) has entered into a senior secured term loan agreement worth up to $150 million with K2 HealthVentures LLC, refinancing its existing debt facility and providing additional financial flexibility as the biotechnology company
Read more
Report
X4 Pharmaceuticals, Inc. Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures LLC
Read more
Report
X4 Pharmaceuticals stock falls 9.33 percent to USD 3.11
X4 Pharmaceuticals stock posted USD 8.806 million in Q2 revenue, compared with USD 2.708 million in Q1. The 4WARD trial target moved from 176 to 126 participants.
Read more
Report
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial -- Expect Completion of Enrollment by Year-End 2026 and...
Read more
Report
Show more news